Delayed puberty medical therapy: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Eiman (talk | contribs)
nocaptcha, Administrators
3,082 edits
No edit summary
Eiman (talk | contribs)
nocaptcha, Administrators
3,082 edits
No edit summary
Line 30: Line 30:
*The aim of treatment is to initiate the [[puberty]] progress and to merge the [[secondary sexual characteristics]] in patients.
*The aim of treatment is to initiate the [[puberty]] progress and to merge the [[secondary sexual characteristics]] in patients.
*Regarding that the delayed [[puberty]] involve only [[Adolescent|adolescents]], all of the therapy options are for them.
*Regarding that the delayed [[puberty]] involve only [[Adolescent|adolescents]], all of the therapy options are for them.
===Delayed puberty===
===Delayed puberty<ref name="PalmertDunkel2012">{{cite journal|last1=Palmert|first1=Mark R.|last2=Dunkel|first2=Leo|title=Delayed Puberty|journal=New England Journal of Medicine|volume=366|issue=5|year=2012|pages=443–453|issn=0028-4793|doi=10.1056/NEJMcp1109290}}</ref>===
*'''1 Stage 1 - Constitutional delay of growth and puberty'''
*'''1 Stage 1 - Constitutional delay of growth and puberty'''
**1.1 '''Boys'''
**1.1 '''Boys'''
Line 65: Line 65:
****Alternative regimen (1): [[Testosterone]] undecanoate 1000 mg IM every 10-14 weeks
****Alternative regimen (1): [[Testosterone]] undecanoate 1000 mg IM every 10-14 weeks
****Alternative regimen (2): [[Testosterone]] gel, apply at bed time
****Alternative regimen (2): [[Testosterone]] gel, apply at bed time
*****Started when approximately 50% adult dose has been achieved with intramuscular testosterone
*****Started when approximately 50% adult dose has been achieved with [[intramuscular]] [[testosterone]]
*****Adult dose 50-80 mg [[transdermal]] per day
****Alternative regimen (3): [[hCG]] plus [[recombinant]] [[FSH]]  
****Alternative regimen (3): [[hCG]] plus [[recombinant]] [[FSH]]  
*****[[hCG]]: 500 to 3000 IU SC or IM twice weekly, increased to every 2 days
*****[[hCG]]: 500 to 3000 IU SC or IM twice weekly, increased to every 2 days
Line 74: Line 73:
*****Initial dose: 2 μg PO per day for 6-12 months
*****Initial dose: 2 μg PO per day for 6-12 months
*****Repeated treatment: Increase every 6-12 months to 5 μg, 10 μg, and 20 μg PO per day
*****Repeated treatment: Increase every 6-12 months to 5 μg, 10 μg, and 20 μg PO per day
*****Adult dose 20 μg PO per day
****Preferred regimen (2): 17β-[[estradiol]] (pill)
****Preferred regimen (2): 17β-[[estradiol]] (pill)
*****Initial dose: 5 μg/kg PO per day for 6-12 months
*****Initial dose: 5 μg/kg PO per day for 6-12 months
*****Repeated treatment: Increase to 10 μg/kg PO per day after 6-12 months, then to 15 μg/kg, and to 20μg/kg per day
*****Repeated treatment: Increase to 10 μg/kg PO per day after 6-12 months, then to 15 μg/kg, and to 20μg/kg per day
*****Adult dose 1-2 mg PO per day
****Preferred regimen (3): 17β-[[estradiol]] ([[transdermal patch]])
****Preferred regimen (3): 17β-[[estradiol]] (transdermal patch)
*****Initial dose: 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day for 6 months  
*****Initial dose: 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day for 6 months  
*****Repeated treatment: Increase 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day every 6 months
*****Repeated treatment: Increase 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day every 6 months
*****Adult dose 50-100 μg transdermal per day
****Preferred regimen (4): [[Conjugated estrogens|Conjugated equine estrogens (CEE)]]  
****Preferred regimen (4): [[Conjugated estrogens|Conjugated equine estrogens (CEE)]]  
*****Initial dose: 0.1625 mg PO per day for 6-12 months  
*****Initial dose: 0.1625 mg PO per day for 6-12 months  
*****Repeated treatment: increase every 6-12 months to 0.325, 0.45, and 0.625 mg PO per day
*****Repeated treatment: Increase every 6-12 months to 0.325, 0.45, and 0.625 mg PO per day
*****Adult dose 0.625 mg PO per day
****Alternative regimen (1): [[Progestogens]]/[[Progestins]] in various formulations, only if treatment last more than 12 months
****Alternative regimen (1): [[Progestogens]]/[[Progestins]] in various formulations, only if treatment last more than 12 months
****Adult dose 5-10 mg of medroxyprogesterone acetate (MPA) PO per day during the last 7 days of menstrual cycle.
****Alternative regimen (2): Micronized [[progesterone]] 100-200 μg PO per day
**2.1 '''Adults'''
**2.1 '''Adults'''
***2.1.1 '''Male'''
***2.1.1 '''Male'''
****Preferred regimen (1): [[Testosterone]] 200 mg IM every 2 weeks
****Preferred regimen (1): [[Testosterone]] 200 mg IM every 2 weeks
****Preferred regimen (2): Pulsatile [[GnRH]]
****Preferred regimen (2): [[Testosterone]] undecanoate 1000 mg IM every 10-14 weeks
****Preferred regimen (3): [[Testosterone]] gel 50-80 mg [[transdermal]] per day
****Alternative regimen (1): Pulsatile [[GnRH]]
*****Initial dose: 5-25 ng/kg/pulse SC every 90-120 min
*****Initial dose: 5-25 ng/kg/pulse SC every 90-120 min
*****Continued treatment: Increase to 25-600 ng/kg/pulse SC every 90-120 min
*****Continued treatment: Increase to 25-600 ng/kg/pulse SC every 90-120 min
****Alternative regimen (3): [[hCG]] plus [[recombinant]] [[FSH]]  
****Alternative regimen (2): [[hCG]] plus [[recombinant]] [[FSH]]  
*****[[hCG]]: 500 to 3000 IU SC or IM twice weekly, increased to every 2 days
*****[[hCG]]: 500 to 3000 IU SC or IM twice weekly, increased to every 2 days
*****rhFSH: 75 to 225 IU SC 2-3 times weekly
*****rhFSH: 75 to 225 IU SC 2-3 times weekly
***2.1.2 '''Female'''
***2.1.2 '''Female'''
****Preferred regimen (1): [[Ethinyl estradiol|Ethinyl estradiol (EE)]]  
****Preferred regimen (1): [[Ethinyl estradiol|Ethinyl estradiol (EE)]] 20 μg PO per day
*****Initial dose: 2 μg PO per day for 6-12 months
****Preferred regimen (2): 17β-[[estradiol]] (pill) 1-2 mg PO per day
*****Repeated treatment: Increase every 6-12 months to 5 μg, 10 μg, and 20 μg PO per day
****Preferred regimen (3): 17β-[[estradiol]] ([[transdermal patch]]) 50-100 μg [[transdermal]] per day
*****Adult dose 20 μg PO per day
****Preferred regimen (4): [[Conjugated estrogens|Conjugated equine estrogens (CEE)]] 0.625 mg PO per day
****Preferred regimen (2): 17β-[[estradiol]] (pill)
****Alternative regimen (1): [[Progestogens]]/[[Progestins]] 5-10 mg of [[Medroxyprogesterone acetate|medroxyprogesterone acetate (MPA)]] PO per day during the last 7 days of menstrual cycle
*****Initial dose: 5 μg/kg PO per day for 6-12 months
*****Repeated treatment: Increase to 10 μg/kg PO per day after 6-12 months, then to 15 μg/kg, and to 20μg/kg per day
*****Adult dose 1-2 mg PO per day
****Preferred regimen (3): 17β-[[estradiol]] (transdermal patch)
*****Initial dose: 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day for 6 months
*****Repeated treatment: Increase 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day every 6 months
*****Adult dose 50-100 μg transdermal per day
****Preferred regimen (4): [[Conjugated estrogens|Conjugated equine estrogens (CEE)]]  
*****Initial dose: 0.1625 mg PO per day for 6-12 months
*****Repeated treatment: increase every 6-12 months to 0.325, 0.45, and 0.625 mg PO per day
*****Adult dose 0.625 mg PO per day
****Alternative regimen (1): [[Progestogens]]/[[Progestins]] in various formulations, only if treatment last more than 12 months
****Adult dose 5-10 mg of medroxyprogesterone acetate (MPA) PO per day during the last 7 days of menstrual cycle.
****Alternative regimen (2): Micronized [[progesterone]] 100-200 μg PO per day
****Alternative regimen (2): Micronized [[progesterone]] 100-200 μg PO per day
==Reference==
==Reference==

Revision as of 21:21, 11 September 2017

Delayed puberty Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Delayed puberty from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Delayed puberty medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Delayed puberty medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Delayed puberty medical therapy

CDC on Delayed puberty medical therapy

Delayed puberty medical therapy in the news

Blogs on Delayed puberty medical therapy

Directions to Hospitals Treating Delayed puberty

Risk calculators and risk factors for Delayed puberty medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Medical Therapy

General approach to pharmacological medical therapy for delayed puberty[1]

 
 
 
 
 
 
 
 
Delayed Puberty
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial assessment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Clinical history
• Physical examinations
• Pubertal phenotype
• Left wrist radiograph for bone age
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unremarkable
 
 
 
 
Abnormal
 
 
 
 
Chronic disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Delayed puberty
• Lack of growth spurt
• Bone age delayed upon chronological age
 
 
 
 
• Possibility of chromosomal disorder
• Bone age may delayed
 
 
 
 
• Chronic disease
• Decreased growth rate or short stature
• Bone age delayed upon chronological age
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis:
• Constitutional delay of growth and puberty (CDGP)
• Gonadotropin deficiency
• Primary gonadal failure
• Extreme athletic exercise
 
 
 
 
Diagnosis:
Girls:
• Turner syndrome
Boys:
• Klinefelter syndrome
 
 
 
 
Diagnosis:
• Hypopituitarism
• Chronic systemic diseases
• Anorexia nervosa
• Malnutrition
• Kallman syndrome
• Iatrogenic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Actions:
• Evaluation hypothalamus-pituitary-gonadal axis
• Consider an MRI to exclude the CNS lesions
 
 
 
 
Actions:
• Chromosome analysis (Karyotyping)
 
 
 
 
Actions:
• Upon the underlying disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment:
1. Psychologic support
2. Observation
3. Sex hormone replacement therapy
 
 
 
 
Treatment:
1. Psychologic support
2. Sex hormone replacement
3. Excision of ovaries in Turner syndrome because of risk of malignancy
 
 
 
 
 
 
 


Delayed puberty[2]

  • 1 Stage 1 - Constitutional delay of growth and puberty
    • 1.1 Boys
      • Preferred regimen (1): Testosterone, not indicated before 14 years of age
        • Initial dose: 50-100 mg IM every 4 weeks for 3-6 months
        • Repeated treatment: To add 25-50 mg in dose (maximum, 100 mg per dose)
      • Preferred regimen (2): Letrozole 2.5 mg PO per day
      • Preferred regimen (3): Anastozole 1mg PO per day
    • 1.2 Girls
      • Preferred regimen (1): Ethinyl estradiol (EE)
        • Initial dose: 2 μg PO per day for 6-12 months
        • Repeated treatment: Increase to 5 μg PO per day after 6-12 months
      • Preferred regimen (2): 17β-estradiol (pill)
        • Initial dose: 5 μg/kg PO per day for 6-12 months
        • Repeated treatment: Increase to 10 μg/kg PO per day after 6-12 months
      • Preferred regimen (3): 17β-estradiol (transdermal patch)
        • Initial dose: 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day for 6 months
        • Repeated treatment: Increase 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day every 6 months
      • Preferred regimen (4): Conjugated equine estrogens (CEE)
        • Initial dose: 0.1625 mg PO per day for 6-12 months
        • Repeated treatment: Titrating to 0.325 mg PO per day after 6-12 months
      • Alternative regimen (1): Progestogens/Progestins in various formulations, only if treatment last more than 12 months
  • 2 Stage 2 - Hypogonadism
    • 2.1 Pediatric
      • 2.1.1 Boys
        • Preferred regimen (1): Testosterone, can be started after 12 years of age
          • Initial dose of 50 mg IM per month
          • Increase with 50 mg in dose IM every 6-12 months
          • After reaching 100-150 mg IM monthly, decrease interval to every 2 weeks
        • Preferred regimen (2): Pulsatile GnRH
          • Initial dose: 5-25 ng/kg/pulse SC every 90-120 min
          • Continued treatment: Increase to 25-600 ng/kg/pulse SC every 90-120 min
        • Alternative regimen (1): Testosterone undecanoate 1000 mg IM every 10-14 weeks
        • Alternative regimen (2): Testosterone gel, apply at bed time
        • Alternative regimen (3): hCG plus recombinant FSH
          • hCG: 500 to 3000 IU SC or IM twice weekly, increased to every 2 days
          • rhFSH: 75 to 225 IU SC 2-3 times weekly
      • 2.1.2 Girls
        • Preferred regimen (1): Ethinyl estradiol (EE)
          • Initial dose: 2 μg PO per day for 6-12 months
          • Repeated treatment: Increase every 6-12 months to 5 μg, 10 μg, and 20 μg PO per day
        • Preferred regimen (2): 17β-estradiol (pill)
          • Initial dose: 5 μg/kg PO per day for 6-12 months
          • Repeated treatment: Increase to 10 μg/kg PO per day after 6-12 months, then to 15 μg/kg, and to 20μg/kg per day
        • Preferred regimen (3): 17β-estradiol (transdermal patch)
          • Initial dose: 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day for 6 months
          • Repeated treatment: Increase 3.1-6.2 μg (1/8-1/4 of 25 μg patch) per day every 6 months
        • Preferred regimen (4): Conjugated equine estrogens (CEE)
          • Initial dose: 0.1625 mg PO per day for 6-12 months
          • Repeated treatment: Increase every 6-12 months to 0.325, 0.45, and 0.625 mg PO per day
        • Alternative regimen (1): Progestogens/Progestins in various formulations, only if treatment last more than 12 months
    • 2.1 Adults

Reference

  1. ↑ Blondell RD, Foster MB, Dave KC (1999). "Disorders of puberty". Am Fam Physician. 60 (1): 209–18, 223–4. PMID 10414639.
  2. ↑ Palmert, Mark R.; Dunkel, Leo (2012). "Delayed Puberty". New England Journal of Medicine. 366 (5): 443–453. doi:10.1056/NEJMcp1109290. ISSN 0028-4793.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Delayed_puberty_medical_therapy&oldid=1350678"